The BTK inhibitor Jaypirca (pirtobrutinib) has been approved in South Korea.

The Ministry of Food and Drug Safety (MFDS) announced on August 19th that it approved Jaypirca, an orphan drug for treating Mantle Cell Lymphoma (MCL). Lilly Korea imports the drug.

Jaypirca works by binding with Bruton's tyrosine kinase (BTK), which is involved in tumor cell proliferation, and inhibiting the BTK activation. Because the drug binds to BTK by mechanism different from existing treatments, it is expected to provide a new treatment opportunity for patients with MCL.

The MFDS designated Jaypirca as the 17th Global Innovative products on Fast Track (GIFT) in September last year and quic